20/20 BioLabs Enters Exclusive U.S. License Agreement
On March 24, 2026, 20/20 BioLabs, Inc., an early market entrant in AI-powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced an exclusive U.S. technology license and access agreement with ROKIT Healthcare Inc., according to GlobeNewswire PE. Under this agreement, 20/20 will integrate ROKIT’s proprietary chronic kidney disease (CKD) prediction algorithm into the 20/20 Longevity Platform to expand its suite of biomarker-based disease-risk assessment tools.
Agreement Terms and Financial Aspects
The agreement includes ROKIT reimbursing 20/20 for one-third of mutually agreed sales and marketing expenses in exchange for a running royalty on net sales of the combined product. The companies also anticipate negotiating a separate agreement that would grant ROKIT exclusive rights to commercialize 20/20’s longevity platform in Korea and potentially other East Asian markets. Clinical evidence indicates that patients with lower systemic inflammation, as measured by biomarkers such as CRP in 20/20’s OneTest for Longevity, may experience better responses to regenerative therapies like ROKIT’s 3-D bio-printed tissue patches for burns, CKD, and heart failure.
Strategic Implications for 20/20 BioLabs
Wonkyung Choi, Vice President of R&D at ROKIT Healthcare, stated that patients treated with ROKIT’s 3-D bio-printed patches for burns or CKD could achieve better outcomes by lowering inflammation through 20/20’s OneTest for Longevity, which involves biomarker tracking and lifestyle changes. This integration enhances 20/20’s position in the longevity-analytics sector by adding CKD prediction capabilities, aiming to provide earlier insights and personalized risk assessments for chronic kidney disease, which affects a significant number of individuals. As widely known in healthcare, early detection of chronic diseases like CKD is crucial for slowing progression, though specific statistics are not detailed in the announcement.
Future Collaborations and Expansion
Jonathan Cohen, President and CEO of 20/20 BioLabs, described the agreement as a validation of their platform strategy, emphasizing the combination of advanced biomarker tools. According to GlobeNewswire PE, this move supports 20/20’s efforts to deliver improved decision-support tools for healthcare providers and individuals.
